semaglutide a glp-1 Shows Secondary Cardiovascular Prevention Benefits in Patients Without Diabetes Semaglutide – GLP-1 Weight Loss

"Medicare Coverage of Anti-Obesity Medications." aspe.hhs.gov Georgetown Medicare Policy Initiative

Both medications are once-weekly injections

Patients are often advised to limit physical activity for a short period following the injection to allow the area to heal properly

effective contraception should be used during treatment Should be discontinued at least 2 months before a planned pregnancy [2] [3] Risk of pancreatitis seek urgent medical attention for severe, persistent abdominal pain Increased risk of gallbladder disease including cholelithiasis and cholecystitis Potential risk of diabetic retinopathy complications in people with type 2 diabetes Risk of hypoglycaemia when used with insulin or sulfonylureas Risk of dehydration leading to acute kidney injury, particularly during initial treatment If you experience side effects, report them through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

Alzheimers Dement Transl Res Clin Interv 5(1):146153